Elma Meershoek‐Klein Kranenbarg
YOU?
Author Swipe
View article: Towards precision rehabilitation medicine after acquired brain injury: Exploring the prediction of patient independence using structured clinical data
Towards precision rehabilitation medicine after acquired brain injury: Exploring the prediction of patient independence using structured clinical data Open
Structured clinical data derived from MFS integration provides a solid foundation for the development of representative in-house developed models to inform and shape care for the target population. This approach advances precision prognosi…
View article: Transfer Learning and Machine Learning for Training Five Year Survival Prognostic Models in Early Breast Cancer
Transfer Learning and Machine Learning for Training Five Year Survival Prognostic Models in Early Breast Cancer Open
Prognostic information is essential for decision-making in breast cancer management. Recently trials have predominantly focused on genomic prognostication tools, even though clinicopathological prognostication is less costly and more widel…
View article: Supplementary Table S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Supplementary Table S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Open
Supplementary Table S1. Representativeness of study participants.
View article: Data from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Data from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Open
Purpose:In hormone receptor–positive, HER2-negative, early-stage breast cancer, cyclin-dependent kinase 4 and 6 inhibition combined with endocrine therapy could represent a less toxic alternative to neoadjuvant chemotherapy (CT). The NEOLB…
View article: Supplementary Appendix S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Supplementary Appendix S1 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Open
Supplementary Appendix S1. Study protocol.
View article: Supplementary Table S2 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Supplementary Table S2 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Open
Supplementary Table S2. Pathological outcome (Ki67% and MP) to either neoadjuvant RL or CT.
View article: Supplementary Table S3 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01)
Supplementary Table S3 from Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Open
Supplementary Table S3. Pathological outcome (Ki67% and MP) to either neoadjuvant RL or CT.
View article: Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)? Open
Combining molecular and clinico-pathologic factors enhances prognostic information. However, the impact of this on actual patient management requires further prospective validation. The trial is registered with clinicaltrials.gov NCT002794…
View article: Consensus on Information Provision for Patients With Early‐Stage Colorectal Cancer: A Delphi Study Among Healthcare Practitioners and Patients
Consensus on Information Provision for Patients With Early‐Stage Colorectal Cancer: A Delphi Study Among Healthcare Practitioners and Patients Open
Background Patients with radically endoscopically treated T1 colorectal cancer (CRC) with at least one high‐risk histopathological characteristic are presented with the choice between additional surgical resection with lymphadenectomy or i…
View article: The <scp>TESTBREAST</scp> journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer
The <span>TESTBREAST</span> journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer Open
Women with an inherited pathogenic variant (PV) in a breast cancer (BC) susceptibility gene, or familial predisposition (FP) have an increased risk to develop BC. There is a need for improvement of screening methods due to interval cancers…
View article: The tumour–stroma ratio as predictive aid towards a biopsy‐based treatment strategy in rectal carcinoma
The tumour–stroma ratio as predictive aid towards a biopsy‐based treatment strategy in rectal carcinoma Open
Aims Tumour–stroma ratio (TSR) scores of biopsy material in rectal carcinoma (RC) could aid a biomarker‐based, upfront and personalised treatment strategy selection for RC patients. In a large retrospective, multicentre cohort, we aimed to…
View article: Perineal wound complications after total neoadjuvant therapy or chemoradiotherapy followed by abdominoperineal excision in patients with high-risk locally advanced rectal cancer in the RAPIDO trial
Perineal wound complications after total neoadjuvant therapy or chemoradiotherapy followed by abdominoperineal excision in patients with high-risk locally advanced rectal cancer in the RAPIDO trial Open
Background Perineal wound complications (PWCs) occur in 15–30% of patients after abdominoperineal excision (APE) and are associated with adverse events, such as delayed wound healing, prolonged hospitalization, a delay in initiating postop…
View article: Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy Open
Importance There is a need for biomarkers that predict late recurrence risk and extended endocrine therapy (EET) benefit among patients with early-stage breast cancer (EBC). MammaPrint, a 70-gene expression risk-of-recurrence assay, has be…
View article: A biopsy-based Immunoscore in patients with treatment-naïve resectable gastric cancer
A biopsy-based Immunoscore in patients with treatment-naïve resectable gastric cancer Open
Background: The prognostic significance of T-cell densities in gastric cancer (GC) was previously demonstrated in surgical resection specimens. For prognosis or response prediction, it is preferable to identify biomarkers in pre-treatment …
View article: Results of a diagnostic imaging audit in a randomised clinical trial in rectal cancer highlight the importance of careful planning and quality control
Results of a diagnostic imaging audit in a randomised clinical trial in rectal cancer highlight the importance of careful planning and quality control Open
Background Magnetic resonance (MR) imaging is the modality used for baseline assessment of locally advanced rectal cancer (LARC) and restaging after neoadjuvant treatment. The overall audited quality of MR imaging in large multicentre tria…
View article: Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial Open
Background Hormone receptor (HR)-positive, HER2/neu-negative breast cancers have a sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane Adjuvant Multinational) is a large, multi-country, phase III trial t…
View article: Data from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
Data from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer Open
Endocrine therapy is important for management of patients with estrogen receptor (ER)–positive breast cancer; however, positive ER staining does not reliably predict therapy response. We assessed the potential to improve prediction of resp…
View article: Supplemental Methods, supplemental tables 1 to 7, and supplemental figures 1 to 9 from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
Supplemental Methods, supplemental tables 1 to 7, and supplemental figures 1 to 9 from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer Open
Supplemental methods on estradiol measurements and sample analysis. Supplemental tables: 1. Public datasets used; 2. Estrogen concentrations on breast tissue; 3. Association of baseline parameters and ERPAS (Edinburgh cohort); 4. Logistic …
View article: Supplemental Methods, supplemental tables 1 to 7, and supplemental figures 1 to 9 from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
Supplemental Methods, supplemental tables 1 to 7, and supplemental figures 1 to 9 from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer Open
Supplemental methods on estradiol measurements and sample analysis. Supplemental tables: 1. Public datasets used; 2. Estrogen concentrations on breast tissue; 3. Association of baseline parameters and ERPAS (Edinburgh cohort); 4. Logistic …
View article: Data from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
Data from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer Open
Endocrine therapy is important for management of patients with estrogen receptor (ER)–positive breast cancer; however, positive ER staining does not reliably predict therapy response. We assessed the potential to improve prediction of resp…
View article: Supplementary Table S1 from Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR<sup>+</sup> Early-stage Breast Cancer for 10 Years of Endocrine Therapy
Supplementary Table S1 from Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR<sup>+</sup> Early-stage Breast Cancer for 10 Years of Endocrine Therapy Open
Kaplan-Meier estimates of risk of recurrence at year 10 since randomization for patients treated with 5 years vs 2.5 years of additional letrozole in the overall cohort and in the Primary AI subset.
View article: Figure S1 from Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR<sup>+</sup> Early-stage Breast Cancer for 10 Years of Endocrine Therapy
Figure S1 from Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR<sup>+</sup> Early-stage Breast Cancer for 10 Years of Endocrine Therapy Open
Forest plot and bar graph of predictive performance of BCI (H/I) in the Overall cohort (N=908) and the Primary AI subset (N=794).